Results 31 to 40 of about 1,093 (174)

Efficacy of Pitolisant on the Treatment of Narcolepsy: A Systematic Review [PDF]

Cureus, 2021
Narcolepsy is characterized by excessive daytime sleepiness (EDS) and cataplexy. Histamine neurons play an important role in enhancing wakefulness. The objective of our study was to evaluate the efficacy of pitolisant, a histamine 3 (H3)-receptor antagonist/inverse agonist, in patients with a high burden of narcolepsy symptoms. We conducted an advanced
Fabara, Stephanie P, Ortiz, Juan Fernando, Anas Sohail, Anas, Hidalgo, Jessica, Altamimi, Abbas, Tama, Belen, Patel, Urvish K   +6 more
openaire   +2 more sources

(A) Pharmacophore hypothesis using pitolisant as a model molecule and, (B) 2D interaction diagram of molecular docking of pitolisant at HDAC2 binding site.

, 2022
(A) Pharmacophore hypothesis using pitolisant as a model molecule and, (B) 2D interaction diagram of molecular docking of pitolisant at HDAC2 binding site.
Bikash Medhi (3908917), Harvinder Singh (2795035), Ajay Prakash (8688492), Nishant Shekhar (8855216), Anupam Raja (12598318)   +4 more
core   +1 more source

Pitolisant in an Adolescent with Prader-Willi Syndrome

The Journal of Pediatric Pharmacology and Therapeutics, 2021
This case report evaluates the potential benefit of pitolisant in a 15-year-old female with Prader-Willi syndrome, obsessive-compulsive disorder, autism spectrum disorder, and mild intellectual disability. Due to its action on the H3 receptor, it enhances central activity of histaminergic neurons resulting in increased alertness, irrespective of the ...
Stephanie, Pennington, Danielle, Stutzman, Elise, Sannar   +2 more
openaire   +3 more sources

Pitolisant, a wake‐promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol

Pharmacology Research & Perspectives, 2021
Several therapeutic options are currently available to treat excessive daytime sleepiness (EDS) in patients suffering from narcolepsy or obstructive sleep apnea.
Stéphane Krief, Isabelle Berrebi‐Bertrand, Isabelle Nagmar, Martin Giret, Simon Belliard, David Perrin, Marilyne Uguen, Philippe Robert, Jeanne‐Marie Lecomte, Jean‐Charles Schwartz, Olivier Finance, Xavier Ligneau   +11 more
doaj   +1 more source

Real-world treatment of pediatric narcolepsy with pitolisant: A retrospective, multicenter study

, 2023
Background: First symptoms of narcolepsy mostly present during childhood. Pharmacological management options in children are limited, also due to approval status.
Lecendreux M., Plazzi G., Kallweit U., Triller A., Lieberich L., Pech de Laclause A., Vandi S., Rezaei R., Pizza F.   +8 more
core   +1 more source

Narcolepsy treatment: from exorcism and bloodletting to modern therapy with histamine receptor inverse agonists

Neurologijos seminarai, 2020
In this review article, we present the treatment of narcolepsy since ancient times when patients experiencing the phenomenon of incubus (today understood as sleep paralysis with hypnagogic or hypnopompic hallucinations) were “cured” during the sessions ...
E. Sakalauskaitė-Juodeikienė, R. Masaitienė   +1 more
doaj   +1 more source

In-silico discovery of dual active molecule to restore synaptic wiring against autism spectrum disorder via HDAC2 and H3R inhibition.

PLoS ONE, 2022
Metal-dependent histone deacetylases (HDACs) are essential epigenetic regulators; their molecular and pharmacological roles in medically critical diseases such as neuropsychiatric disorders, neurodegeneration, and cancer are being studied globally. HDAC2'
Anupam Raja, Nishant Shekhar, Harvinder Singh, Ajay Prakash, Bikash Medhi   +4 more
doaj   +3 more sources

Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 study. [PDF]

J Sleep Res
International audienceSummary Obstructive sleep apnea (OSA) syndrome commonly leads to excessive daytime sleepiness (EDS). Pitolisant, a selective histamine‐3 receptor antagonist, is efficacious at doses up to 20 mg once daily in OSA treated or not with ...
Dauvilliers Y, Craig SE, Bonsignore MR, Barbé F, Verbraecken J, Asin J, Georgiev O, Tiholov R, Caussé C, Lecomte JM, Schwartz JC, Lehert P, Randerath W, Pépin JL, HAROSA III Study Group.   +14 more
europepmc   +4 more sources

Pitolisant: A Review in Narcolepsy with or without Cataplexy

, 2020
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflict of interest: Yvette Lamb is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content ...
Yvette Lamb (6930427)
core   +1 more source

Pitolisant protects mice chronically treated with corticosterone from some behavioral but not metabolic changes in corticosterone-induced depression model [PDF]

, 2020
Purpose: Histamine H3 receptor ligands may have antidepressant and anxiolytic effects. They can also compensate for metabolic disorders, which affect glucose or triglyceride levels.
Mika, Kamil, Sapa, Jacek, Kotańska, Magdalena, Wheeler, Lee, Kieć-Kononowicz, Katarzyna, Pytka, Karolina, Sałaciak, Kinga   +6 more
core   +3 more sources